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Abstract
Background: In past, numerous quantitative structure-activity relationship (QSAR) based models have been developed
for predicting anticancer activity for a specific class of molecules against different cancer drug targets. In contrast, limited
attempt have been made to predict the anticancer activity of a diverse class of chemicals against a wide variety
of cancer cell lines. In this study, we described a hybrid method developed on thousands of anticancer and
non-anticancer molecules tested against National Cancer Institute (NCI) 60 cancer cell lines.
Results: Our analysis of anticancer molecules revealed that majority of anticancer molecules contains 18–24
carbon atoms and are dominated by functional groups like R2NH, R3N, ROH, RCOR, and ROR. It was also observed
that certain substructures (e.g., 1-methoxy-4-methylbenzene, 1-methoxy benzene, Nitrobenzene, Indole, Propenyl
benzene) are more abundant in anticancer molecules. Next, we developed anticancer molecule prediction
models using various machine-learning techniques and achieved maximum matthews correlation coefficient
(MCC) of 0.81 with 90.40 % accuracy using support vector machine (SVM) based models. In another approach, a
novel similarity or potency score based method has been developed using selected fragments/fingerprints and
achieved maximum MCC of 0.82 with 90.65 % accuracy. Finally, we combined the strength of above methods
and developed a hybrid method with maximum MCC of 0.85 with 92.47 % accuracy.
Conclusions: We developed a hybrid method utilizing the best of machine learning and potency score based
method. The highly accurate hybrid method can be used for classification of anticancer and non-anticancer
molecules. In order to facilitate scientific community working in the field of anticancer drug discovery, we
integrate hybrid and potency method in a web server CancerIN. This server provides various facilities that
includes; virtual screening of anticancer molecules, analog based drug design, and similarity with known
anticancer molecules (http://crdd.osdd.net/oscadd/cancerin).
Keywords: Cancer inhibitors, Classification of cancer inhibitors and non-inhibitors, Active substructure, Active
functional groups, Fingerprints, QSAR, Potency score, SVM light
Background
One of the major challenges in the field of drug discov-
ery is to design effective drugs against cancer. Existing
drugs have their limitations that includes, side effects of
drugs, high toxicity, drug resistance towards current an-
ticancer drugs [1]. There is a pressing need to improve
the drug arsenal to fight against this deadly disease. Ex-
perimental techniques used for drug discovery are costly
and time-consuming. Thus, there is a need to develop in
silico techniques for designing anticancer drugs.
In the past, attempts have been made to develop com-
putational methods to design/predict anticancer mole-
cules. Recently, various studies modelled the drug
behaviour against multiple cancer cell lines using differ-
ent genomics features. Based on the genomic data i.e.,
DNA copy number, gene expression, mutations and
methylation the drug sensitivity is predicted. Either sin-
gle gene features predict the drug sensitivity or multi-
gene features [2–9]. In spite of advances in genomics,
modelling the behaviour of thousands of drug is still a
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challenging task. The other approach is quantitative
structure-activity relationship (QSAR) based models,
where chemical features are used to predict inhibitors
against specific cancer drug targets [10–18]. Most of the
QSAR-based models have been developed for predicting
inhibition activity of a specific class of molecules against
a given drug target [19–23]. Recently, QSAR-based
models have been developed for inhibition activity pre-
diction of any class of molecule (irrespective of mole-
cules class) against cancer drug target EGFR [24]. In
contrast, limited attempt have been made to develop
methods for predicting the anticancer activity of mole-
cules against cancer cell lines. Kumar et al. developed
one such method against 16 pancreatic cancer cell lines,
which consider cancer cell as a whole for the anticancer
activity irrespective of drug targets [25].
Development Therapeutics Program (DTP) stores
thousands of molecules tested against NCI-60 human
cancer cell lines [26]. Researchers have exploited this
massive dataset for various studies like a prediction of
anticancer molecules. Josefin and coworkers showed that
molecules with similar activity profiles or structure often
show similar mode of action (MOA) [27]. Recently, Li
et. al. have developed a method called CDRUG [28], for
predicting the potential anticancer molecules using the
NCI-60 data. They developed similarity-based approach
using relative frequency-weighted fingerprints, Tanimoto
coefficient, and MinMax Kernel and achieved area under
the curve (AUC) value of 0.88. CDRUG is based upon
thousands of fingerprints generated using jCompound-
Mapper [29] and offers little understanding of the algo-
rithm. Further, JCompoundMapper package generates
only chemical graph fingerprints with no substructure-
based fingerprint. In this study, a systematic attempt has
been made to develop a method for predicting antican-
cer molecules. Here, we have used a large dataset
containing 8565 anticancer and 9804 non-anticancer
molecules obtained from NCI-60 [28]. Using this large
dataset, we identify important fingerprints/substruc-
tures that play a significant role in the classification
of anticancer and non-anticancer molecules. We de-
veloped a hybrid method by combining the machine
learning and similarity-based method developed on




Dataset used in this study was taken from Li and Huang
study [28], which consists of 8565 anticancer and 9804
non-anticancer molecules. This dataset is compiled from
the NCI-60 DTP project, and it is available at http://
bsb.kiz.ac.cn/site_media/download/CDRUG/Benchmark.
rar. In NCI-60 DTP project, two-stage screening of
molecules was carried out. In the first stage, all the
molecules were screened on 60 cell lines at 10−5 molar
(15 μg/ml). Molecules showing significant growth inhib-
ition were further tested on NCI-60 at five different
concentrations. The results of screening were analyzed
by NCI COMPARE algorithm [30].
Fingerprint calculation
PaDEL software [31] was used to calculate fingerprints,
which calculates ten types of fingerprints viz. CDK,
Estate fingerprints, MACCS fingerprints, PubChem fin-
gerprints, substructure fingerprint and Klekota-Foth fin-
gerprints and their respective counts. The details about
PaDEL package and different fingerprints are available at
PaDEL website.
Fingerprint or feature selection
In this study, we used an MCC-based approach for
feature selection, where mean of each fingerprint in
active and inactive dataset was calculated using the

















I represent mean of ith fingerprint in
active (A) and inactive (I) molecules respectively. NA
and NI is the number of molecules in active and inactive
datasets respectively. Di
j is the value of ith fingerprint for
the jth molecule (value is either 0 or 1). For active mole-
cules, j varies from 1 to NA and for inactive molecules j
varies from 1 to NI. Next, we classify the anticancer and
non-anticancer molecules based on the compound score
(Cscore) of a single fingerprint. If the value of fingerprint
is 1, Cscore is the difference between Fi
A and Fi
I, else the
Cscore is the difference between Fi
I and Fi
A. Following




i ; if Di ¼ 1
FIi−F
A
i ; if Di ¼ 0
ð3Þ
(
Where Cjscore is a compound score of the j
th molecule
for ith fingerprint. Each molecule is having, Cscore more
than threshold was classified as active, otherwise classi-
fied as inactive molecule. This technique was repeated
for each fingerprint at the different threshold. Finally,
the performance of each fingerprint is computed in
terms of MCC value.
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Calculation of similarity
In order to compute similarity between two molecules,
we calculated Tanimoto similarity score between two
molecules using following equation







Where Ts is the Tanimoto similarity score between
compound X and Y; Xi and Yi is fingerprint i of com-
pound X and Y, respectively; N is total number of finger-
prints. In this study, we computed two types of
Tanimoto similarity scores called Ts1 and Ts0. The Ts1
was calculated for fingerprint present (value 1) in the
molecule and Ts0 based upon the fingerprint absent
(value 0) in the molecule.
Potency score
The potency score of a query molecule was computed
using following steps:
1) First, we computed Tanimoto similarity score Ts1
between query compounds with each of anticancer
molecules and selected highest Ts1 called H
aTs1.
2) Similarly, we also computed highest similarity score
HaTs0 between the query and most similar
anticancer molecules based on Ts0.
3) Above steps were repeated to compute similarity
scores HnTs1 and H
nTs0 between the query and most
similar non-anticancer molecule.
4) Finally, potency score was computed using following
equation
Ps ¼ max HaTs1;HaTs0ð Þ‐max HnTs1;HnTs0ð Þ ð5Þ
Where Ps is the potency score of the query molecule
and max is the maximum or highest score. If HaTs1 has
q high score as compared to HaTs0, then it is the max-
imum score (max) of the anticancer molecule. Similarly,
max score of non-anticancer molecules was selected
based on the highest score of either HnTs1 or H
nTs0. The
advantage of using potency score instead of normal
Tanimoto score is that it provides the structural similar-
ity information of query molecule with anticancer, as
well as with non-anticancer molecules.
Frequency of functional groups
Functional groups were identified using the ChemmineR
package of R [33]. The percent of compounds having
specific functional groups was calculated using eq. 6. We
also calculated the mean count of functional groups in















Where MG is the mean count of a functional group
(G) in total number (n) of anticancer or non-anticancer
compounds. Ci
j is total count of a functional group (G)
for the jth compound with i value ranges from zero to
maximum number of occurrence of functional group in
a compound. The FG is the mean frequency of a func-
tional group (G) in total number (n) of anticancer or
non-anticancer compounds with Pi
j stands for presence
or absence (value is either 0 or 1) of a functional group.
Classification
For a comparison of potency score method with ma-
chine learning methods, we also developed models using
various classifiers in WEKA package [34]. We also com-
pare the performance of our method with SVM package
[35]. For improving the overall performance, we devel-
oped the hybrid method by doing an average of the nor-
malized potency score and SVM score. Since, the scale
of potency score and SVM value are different, we nor-
malized these values between −1.0 and 1.0.
Performance evaluation
We have adopted the five-fold cross-validation technique
to evaluate the performance of our models. In this tech-
nique, the compounds were randomly divided into five
parts, where four parts were used for training and
remaining part for testing. This process is carried out
five times in such a way that each part was used once
for testing. For obtaining unbiased results, the whole
process of five-fold cross-validation was repeated 20
times. We report the final results as the average of 25-
fold cross-validations. The performance of the method
was assessed using various standard parameters like sen-
sitivity, specificity, accuracy, and Matthews correlation
coefficient (MCC) [36]. The receiver operating charac-
teristic (ROC) graph was plotted using the ROCR pack-
age in R [37].
Ethics
The study doesn’t involve any human, plant or animal
subject. All the experiments were carried out using com-
putational techniques.
Results
Frequency of functional groups
We tried to find out the predisposition of various func-
tional groups in anticancer and non-anticancer molecules.
Functional groups were identified using the ChemmineR
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package of R [33] and percentage of groups in compounds
were computed using eq. 6. It was observed that certain
functional groups (e.g., ROH, RCOR, RCOOR, ROR) have
higher frequency and are predominantly present in anti-
cancer molecules. These groups may be responsible for
the anticancer activity of these active molecules as shown
in Fig. 1. These functional groups can be further explored
in designing of promiscuous anticancer molecules. We
also calculated the total count of functional groups
present in anticancer and non-anticancer molecules. It
was observed that ROR group frequency range from 0 to
15 (maximum ROR was observed in a compound) as
shown in Additional file 1: Figure S1. Further, we tried to
find out the pharmacophore of most active molecules,
which could be responsible for the anticancer activity.
We aligned the top 20 molecules (in terms of activity)
by PharmaGist software [38] and selected the most
significant alignment (PharmaGist score of 77.61).
This alignment identified total 18 features, which in-
clude twelve hydrogen bond acceptors, four aromatic,
one hydrophobic and one hydrogen bond donor as
shown in Fig. 2.
Maximum common substructures (MCS)
We also determined the maximum common substruc-
tures in anticancer molecules using the LibMCS module
of Chemaxon (http://www.chemaxon.com/). The ana-
lysis shown in Fig. 3 depicts the frequently occurring
Maximum Common Substructures (MCS). The number
beneath each MCS represents the total number of mole-
cules in which that particular substructure was present
according to MCS module. The 1st substructure is 1-
methoxy-4-methylbenzene i.e., (methyl group is present
at para position). The 2nd substructure is a part of
known tyrosine kinase inhibitors like Imatinib and Nilo-
tinib. The 6th substructure is indole structure, which is
used for designing inhibitors against kinases especially
EGFR [39]. The 3rd, 4th, 5th, 6th, 7th, 8th and 9th sub-
structures are acetophenone, 1-methoxy benzene with
partial double bond at meta position, nitrobenzene, in-
dole, propenyl benzene, butyl benzene and dimethylani-
line. We also calculate frequency of occurrences of these
MCS in anticancer and non-anticancer compounds using
substructure search option of jcsearch module of Che-
maxon (Additional file 1: Table S1). The most popular
Fig. 1 Functional groups present in anticancer and non-anticancer molecules along with their mean frequency
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common substructure 1-methoxy-4-methylbenzene found
in 1115 (13.02 %) anticancer and 577 (5.89 %) non-
anticancer (5.89 %) compound. Most of MCS have higher
frequency in anticancer compounds as compare to non-
anticancer compound.
Analysis of fingerprints
In order to identify the best fingerprints, which are more
abundant in anticancer or non-anticancer molecules, we
used the MCC-based feature selection technique as de-
scribed in Methods section. In brief MCC based feature
selection involves two major steps; in first step the per-
formance of each fingerprint is computed in terms of
MCC; in 2nd step, fingerprints are ranked based on their
MCC score [32]. In this study, we selected fingerprints
having MCC score greater than 0.2 for the development
of the model. It was observed that PubChem fingerprint
number 12 is among the best fingerprints that can clas-
sify anticancer and non-anticancer molecules with an
accuracy of 71.69 %. This fingerprint represents the
presence of > = 16 carbon atoms in a compound. The
best ten fingerprints along with their classification per-
formance of anticancer and non-anticancer compounds
are shown in Table 1. The detailed results of 126 finger-
prints are given in Additional file 1: Table S2. It was ob-
served that few CDK fingerprints are also efficient in
distinguishing anticancer and non-anticancer molecules.
Potency score based classification
In the current study, we compute the performance of
models using five-fold cross validation technique with
20 runs as described by Li et. al. We selected the best
fingerprints out of 9365 fingerprints for accurate, un-
biased and quick development of classification method
using MCC feature selection. First, we develop potency
score based method using top 50 fingerprints having the
highest MCC score. The best 50 fingerprints based
method achieved 86.94 % accuracy with 0.74 MCC.
Next, we developed method using best 100, 150 and 200
fingerprints and achieved 89.48 %, 90.1 %, 90.16 % ac-
curacy respectively (Table 2). It was observed that using
more than 150 fingerprints; there is no increase in per-
formance of the method. Finally, we selected the finger-
prints having MCC greater than 0.2 and obtained 126
fingerprints. We used these 126 fingerprints for develop-
ing prediction models and achieved 90.94 % accuracy
with 0.82 MCC.
Models based on machine learning techniques
In order to discriminate anticancer and non-anticancer
molecules, we developed classification models using
various machine learning techniques. The performance
of models developed using different classifiers imple-
mented in WEKA (i.e., Random forest, IBK, Naïve
Bayes) and SVMlight [35, 40] has been shown in Table 3.
The SVM-based models achieved highest accuracy
90.40 % with MCC 0.81 among all classifiers. The Ran-
dom forest, IBK and Naïve Bayes based method achieved
the highest accuracy in the range of 74.92–87.47 %. The
models based on SVM and Random Forest achieved the
best performance at the center of threshold and had
broad range of MCC across various thresholds. The
Random forest method achieved best performance using
100 trees; best SVM model trained using RBF kernel
with parameter g = 0.1, c = 6 with j = 1; IBK method
achieved best performance using kNN score of 3 with
Manhattan distance algorithm.
Performance of hybrid models
As shown in both potency score based method and
SVM-based model achieved maximum accuracy. The
potency score method performs better, when query mol-
ecule is similar with anticancer molecules but perform
poorly in case level of similarity is low. In case of SVM,
the performance of the model is unaffected by similarity
with known molecules. As shown in ROC curve at lower
Fig. 3 Maximum common substructures found in anticancer molecules along with the number of molecules having that particular substructure
Fig. 2 Pharmocophore alignment of most active anticancer
molecules generated using PharmaGist
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false positive rate (FPR), potency score performs better
than SVM and at higher FPR, SVM perform better than
potency score based method (Fig. 4). In order to take
the advantage of potency score and SVM method, we
developed the hybrid method. In case of hybrid method,
first we compute SVM potency score of a query mol-
ecule and normalize these scores between −1.0 and 1.0.
The average of normalize values is computed to obtain
the hybrid score and used for predicting anticancer mol-
ecule. We developed a hybrid method using 126 best fin-
gerprints and achieved highest MCC 0.85 with 0.98
AUC. The detail result of hybrid method are shown in
Additional file 1: Table S3.
Comparison with existing method
We compared the performance of our methods with
existing method CDRUG. The CDRUG developed by Li
et. al. achieved 65 %, 74 %, 81 % sensitivity at false posi-
tive rate (FPR) 0.05, 0.1, 0.2 respectively (Table 4). At
65 % sensitivity, both potency score method and SVM
achieved 0.02 FPR and hybrid method achieved 0.01
FPR. As shown in Table 4, our models perform better
than existing method CDRUG.
Description of the web server
In order to serve the scientific community, we developed
a web server called “CancerIN” for predicting the
anticancer potency of an unknown molecule and it’s
GI50 across different cancer cell lines. This web server
consists of three modules for designing, library screening
and chemical analogs screening.
Draw molecule
This web server provides a user-friendly interface with
options to draw a chemical compound using Marvin
applet as shown in (Fig. 5a) [41]. The output consists of
a 3D structure of query molecule with physicochemical
properties and hybrid score. The five most similar anti-
cancer molecules along with their NSC ID, PubChem
ID, Mean_logGI50, Tanimoto similarity score, Potency
score and physicochemical properties are also displayed.
The details button provides the GI50 and LogGI50 score
of similar molecule against different NCI-60 cancer cell
lines. The user can select and further load either query
molecule or any five similar molecules for further modi-
fications based upon the structural similarity (Fig. 5c).
The modified molecule can be further used as query
molecule for increasing its potential anticancer activity.
Scan library
This web server also provides the provision to scan a
chemical library in SMILES format [42]. The output
consists of query molecule and five most similar antican-
cer molecules along with their other details as described
above in tabular format (Fig. 5d).
Chemical analogs
We have also provided facility for the users to screen an-
alogs generated from different combination of scaffold,
building blocks and linkers using SmiLib [43] package
(Fig. 5b) and subsequent prediction of their anticancer
potency score. The results consist of query molecule and
five most similar anticancer molecules in a tabular
format.
Standalone
For the screening of thousands of molecules, we have
developed CancerIN standalone, written in Python. The
standalone version can screen thousands of molecules in
less than 10 min. The input consists of a single file hav-
ing chemical structures (SMILE format) of molecules for
screening. The standalone version can be easily updated
by replacing the underlying data file. The user can easily
increase or decrease the number of fingerprints used for
final prediction. The source code allows the scientific
community to utilize the novel similarity-based method
for prediction of various types of molecules.
In brief, the CancerIN web server predicts the antican-
cer capability of a single molecule, a library of chemicals
or analogs. Since, our method also consider similarity, it
also displays the GI50 of the similar anticancer molecule
Table 2 The performance of potency score based method
developed using different sets of fingerprints
Number of
fingerprints
Sensitivity Specificity Accuracy MCC FPR ROC
50 79.59 93.37 86.94 0.74 0.09 0.92
100 82.36 95.7 89.48 0.79 0.06 0.95
150 83.17 96.15 90.1 0.81 0.05 0.95
200 83.14 96.3 90.16 0.81 0.05 0.95
126 84.62 96.45 90.94 0.82 0.05 0.95
Table 1 The individual performance of best 10 selected
fingerprints using MCC based approach
Best 10 fingerprints Sensitivity Specificity Accuracy MCC FPR AUC
PubchemFP12 79.3 65.1 71.69 0.45 0.48 0.72
ExtFP1013 52.5 85.7 70.19 0.41 0.65 0.69
ExtFP1012 78.4 61.9 69.61 0.41 0.47 0.7
PubchemFP192 58.4 79.4 69.6 0.39 0.61 0.69
GraphFP382 73.3 63.8 68.27 0.37 0.50 0.69
ExtFP1016 42 88.7 66.91 0.35 0.71 0.65
PubchemFP199 28.1 95.4 64.01 0.32 0.80 0.62
ExtFP1015 70.7 61.5 65.77 0.32 0.50 0.66
MACCSFP105 70.1 60.6 64.98 0.31 0.50 0.65
FP799 34.7 89.6 64.01 0.29 0.75 0.62
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Table 3 Comparative performance of models developed using 126 fingerprints at various thresholds has been shown in this table
SVM Random Forest IBK Naïve Bayes
Threshold Accuracy MCC Threshold Accuracy MCC Accuracy MCC Accuracy MCC
−1 72.40 0.54 0 46.63 0.00 46.63 0.00 46.63 0.00
−0.8 80.58 0.65 0.1 67.74 0.47 80.22 0.63 75.06 0.50
−0.6 84.72 0.72 0.2 77.73 0.61 82.59 0.67 74.99 0.50
−0.4 87.52 0.76 0.3 83.71 0.69 83.98 0.68 74.98 0.50
−0.2 89.60 0.79 0.4 86.33 0.73 85.71 0.72 74.92 0.50
0 90.40 0.81 0.5 87.47 0.75 85.31 0.71 74.86 0.49
0.2 90.24 0.80 0.6 86.47 0.73 85.10 0.71 74.79 0.49
0.4 89.00 0.79 0.7 83.81 0.69 82.73 0.67 74.79 0.49
0.6 86.35 0.74 0.8 79.03 0.62 81.22 0.65 74.81 0.49
0.8 82.65 0.68 0.9 71.86 0.51 80.90 0.65 74.77 0.49
1.0 70.49 0.48 1.0 59.30 0.28 80.87 0.65 73.37 0.48
Fig. 4 ROC plot of potency score, SVM and hybrid method developed using 126 fingerprints
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across different cancer cell lines. A careful analysis of
the anticancer efficacy of five similar molecules aids in
understanding the anticancer efficacy of query molecule
against various cancer cell lines. The standalone version
of CancerIN allows the users to scan a vast library of
molecules for the screening of potential anticancer mol-
ecules. This standalone is available at CancerIN website
http://crdd.osdd.net/oscadd/cancerin.
Discussion and conclusion
The continuous development of novel anticancer drugs
is imperative in order to tackle multi-drug resistance in
cancer. At the same time, the development of an anti-
cancer drug is very time-consuming, expensive and
labor-intensive task. However, an integrated approach
consisting of both computational and experimental ap-
proaches would be of great significance. Computational
approaches are very helpful to identify or to narrow
down potential lead molecules in a very short period
without involving much money. Subsequently, the ex-
perimental approach may be used to validate these pre-
dictions. In this study, we developed QSAR models by
Fig. 5 Various modules of CancerIN showing the input format and output display: a The Marvin draw applet for drawing molecules, b The input
form for generation of analogs, c The output page of draw molecule module, and d. The result page of scan library showing the list of query
molecules and the most similar anticancer molecules
Table 4 Comparative performance of CDRUG (existing method)
and our models based on potency score, SVM and hybrid
approach
Method Sensitivity Specificity Accuracy MCC FPR AUC
CDRUG 65 - - - 0.05 0.88
74 0.10
81 - - - 0.20
Potency Score 65.8 98.9 83.5 0.7 0.02 0.95
74.26 98.42 87.15 0.76 0.02
84.62 96.45 90.94 0.82 0.05
SVM 65.47 98.66 83.34 0.69 0.02 0.95
74.16 97.63 86.8 0.75 0.03
89.02 91.52 90.42 0.81 0.09
Hybrid 65.57 99.63 83.75 0.71 0.01 0.98
74.41 99.11 87.59 0.77 0.01
92.38 92.55 92.47 0.85 0.08
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considering the whole cell for anticancer activity for any
class of molecules. The aim of the present study was to
develop an efficient in silico method for screening of an-
ticancer molecules against NCI-60 cancer cell lines.
Thus, our method is a general method for predicting an-
ticancer molecules irrespective of drug target or cell line.
The performance of potency score method introduced in
this study is comparable with models developed using
machine-learning classifiers (e.g., Random forest, SVM,
IBK and Naïve Bayes). We further improve the perform-
ance of our method by combining potency-score based
model and SVM based method. In past, a method
CDRUG has been developed on same dataset of chemicals
for predicting anticancer molecules. Our best models
outperform existing method CDRUG. Finally, we inte-
grated these models in a web server for the betterment
of scientific society working in this field.
Additional files
Additional file 1: Figure S1. Counts of Functional groups present in
anticancer and non-anticancer molecules. Table S1. Shows frequency of
occurrence of MCS in anticancer and non-anticancer compounds according
to LibMCS module of Chemaxon. Structures were search using jcsearch
module of Chemaxon with substructure search option. Table S2. The
individual performance of best 126 selected fingerprints using MCC based
approach. Table S3. Performance of hybrid method developed using 126
fingerprints on different sensitivity. (DOC 356 kb)
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